Overview

Safety and Tolerability of RTX-134 in Adults With Phenylketonuria

Status:
Active, not recruiting
Trial end date:
2035-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of RTX-134 in adult patients with PKU.
Phase:
Phase 1
Details
Lead Sponsor:
Rubius Therapeutics